Rituximab biosimilar - Boehringer Ingelheim

Drug Profile

Rituximab biosimilar - Boehringer Ingelheim

Alternative Names: BI-695500

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma; Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2016 Boehringer Ingelheim terminates a phase III trial for Follicular lymphoma (First-line therapy) in USA (NCT02417129)
  • 01 Dec 2015 Boehringer completes a phase I trial in Follicular lymphoma (First-line therapy) in Austria, Australia, Belgium, Croatia, Czech Republic, Germany, France, Greece, Hungary, Poland, Russia, Slovakia, Spain and New Zealand (IV) (NCT01950273)
  • 19 May 2015 Rituximab biosimilar is still in phase-III development for Rheumatoid arthritis in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top